

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-95 (canceled)

96. (currently amended) An antibody that specifically binds to PSCA of SEQ ID NO. 2 SEQ ID NO. 2 and which binds to a cell that expresses PSCA ~~protein and protein~~ and achieves an effect selected from the group consisting of:

- a. (a) kills the cell to which it specifically binds;
- b. (b) reduces tumor ~~burden~~ volume of a tumor which comprises cells that express PSCA of SEQ ID NO. 2, upon specific binding of the antibody to the cell;
- c. (c) is internalized within the cell to which it specifically binds; and/or
- d. (d) is cytostatic to the cell to which it specifically binds.

97. (currently amended) An antibody of claim 96 which kills the cell to which it specifically binds.

98. (currently amended) An antibody of claim 96 which is internalized within the cell to which it specifically binds.

99. (currently amended) An antibody of claim 96 which is cytostatic to the cell to which it specifically binds.

100. (previously presented) An antibody of claim 96 which is monoclonal.

101. (previously presented) A hybridoma that produces the antibody of claim 100.

102. (previously presented) An antibody of claim 96, which is a human antibody.

103. (previously presented) An antibody of claim 96, which is a chimeric antibody.

104, (new) An antibody of claim 100, which is humanized.

105. (new) An antibody of claim 96 that reduces tumor volume.